
## Giuseppe Lucio Cascini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7339747/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer, 2007, 57, 125-134.	2.0	158
2	The Copper Radioisotopes: A Systematic Review with Special Interest to <sup>64</sup> Cu. BioMed Research International, 2014, 2014, 1-9.	1.9	63
3	Structural connectivity differences in motor network between tremor-dominant and nontremor Parkinson's disease. Human Brain Mapping, 2017, 38, 4716-4729.	3.6	57
4	Combined use of DAT‧PECT and cardiac MIBG scintigraphy in mixed tremors. Movement Disorders, 2009, 24, 2242-2248.	3.9	56
5	Bone Metastases Radiopharmaceuticals: An Overview. Current Radiopharmaceuticals, 2013, 6, 41-47.	0.8	54
6	PET/CT with 18 F–choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients. Nuclear Medicine and Biology, 2017, 51, 40-54.	0.6	49
7	<sup>124</sup> lodine: A Longer-Life Positron Emitter Isotope—New Opportunities in Molecular Imaging. BioMed Research International, 2014, 2014, 1-7.	1.9	45
8	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	1.0	42
9	Peptide Imaging with Somatostatin Analogues: More than Cancer Probes. Current Radiopharmaceuticals, 2013, 6, 36-40.	0.8	35
10	Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study. Radiologia Medica, 2013, 118, 930-948.	7.7	33
11	Effect of aging on magnetic resonance measures differentiating progressive supranuclear palsy from Parkinson's disease. Movement Disorders, 2014, 29, 488-495.	3.9	33
12	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clinical Genitourinary Cancer, 2018, 16, 385-391.	1.9	33
13	Advanced Imaging Techniques for Radiotherapy Planning of Gliomas. Cancers, 2021, 13, 1063.	3.7	31
14	Myocardial 123I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiology of Aging, 2010, 31, 1903-1911.	3.1	30
15	Microvascular Invasion in HCC: The Molecular Imaging Perspective. Contrast Media and Molecular Imaging, 2018, 2018, 1-10.	0.8	30
16	Molecular imaging of brain tumors with radiolabeled choline PET. Neurosurgical Review, 2018, 41, 67-76.	2.4	29
17	CADA—computer-aided DaTSCAN analysis. EJNMMI Physics, 2016, 3, 4.	2.7	28
18	Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine. Current Pharmaceutical Design, 2015, 21, 4738-4747.	1.9	28

#	Article	IF	CITATIONS
19	Initial Staging of Lymphoma With Octreotide and Other Receptor Imaging Agents. Seminars in Nuclear Medicine, 2005, 35, 176-185.	4.6	27
20	Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET. Neuro-Oncology, 2021, 23, 1024-1034.	1.2	26
21	Reduction in Global Myocardial Glucose Metabolism in Subjects With 1-Hour Postload Hyperglycemia and Impaired Glucose Tolerance. Diabetes Care, 2020, 43, 669-676.	8.6	25
22	Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence. Hellenic Journal of Nuclear Medicine, 2015, 18, 152-6.	0.3	25
23	New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology. Current Radiopharmaceuticals, 2013, 6, 117-123.	0.8	22
24	The Molecular Effects of Ionizing Radiations on Brain Cells: Radiation Necrosis vs. Tumor Recurrence. Diagnostics, 2019, 9, 127.	2.6	19
25	Methodologies for the analysis and classification of PET neuroimages. Network Modeling Analysis in Health Informatics and Bioinformatics, 2013, 2, 191-208.	2.1	17
26	Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome. Parkinsonism and Related Disorders, 2018, 56, 20-26.	2.2	17
27	Fever of unknown origin, infection of subcutaneous devices, brain abscesses and endocarditis. Nuclear Medicine Communications, 2006, 27, 213-222.	1.1	16
28	Dopamineâ€ŧransporter levels drive striatal responses to apomorphine in <scp>P</scp> arkinson's disease. Brain and Behavior, 2013, 3, 249-262.	2.2	16
29	Microstructural changes of normal-appearing white matter in Vascular Parkinsonism. Parkinsonism and Related Disorders, 2019, 63, 60-65.	2.2	16
30	Alterations of putaminal shape in de novo Parkinson's disease. Movement Disorders, 2016, 31, 676-683.	3.9	15
31	Experiences on quantitative cardiac PET analysis. , 2016, , .		15
32	Cardiac MIBG scintigraphy in Primary Progressive Freezing Gait. Parkinsonism and Related Disorders, 2009, 15, 365-369.	2.2	14
33	Unexpected Detection of Melanoma Brain Metastasis by PET With Iodine-124 βCIT. Clinical Nuclear Medicine, 2009, 34, 698-699.	1.3	13
34	Value of Multimodal Imaging Approach to Diagnosis of Neurosarcoidosis. Brain Sciences, 2019, 9, 243.	2.3	13
35	Impact of [64Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report. BMC Cancer, 2019, 19, 1197.	2.6	13
36	68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers. Current Radiopharmaceuticals, 2019, 12, 238-246.	0.8	10

#	Article	IF	CITATIONS
37	Metabolic Syndrome Is Associated With Impaired Insulin-Stimulated Myocardial Glucose Metabolic Rate in Individuals With Type 2 Diabetes: A Cardiac Dynamic 18F-FDG-PET Study. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	10
38	Mixed tremors with integrity of nigrostriatal system: A clinical and DAT‧PECT followâ€up study. Movement Disorders, 2010, 25, 662-664.	3.9	9
39	123I-mIBG imaging predicts functional improvement and clinical outcome in patients with heart failure and CRT implantation. International Journal of Cardiology, 2016, 207, 107-109.	1.7	9
40	lctal 18F-FDG PET/MRI in a Patient With Cortical Heterotopia and Focal Epilepsy. Clinical Nuclear Medicine, 2017, 42, 768-769.	1.3	8
41	A case of Fahr's disease examined by multi-modal imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 2098-2099.	6.4	7
42	Nuclear medicine in multiple myeloma more than diagnosis. Nuclear Medicine Review, 2010, 13, 32-8.	0.5	7
43	Neuroimaging and Neurolaw: Drawing the Future of Aging. Frontiers in Endocrinology, 2019, 10, 217.	3.5	5
44	Track density imaging: A reliable method to assess white matter changes in Progressive Supranuclear Palsy with predominant parkinsonism. Parkinsonism and Related Disorders, 2019, 69, 23-29.	2.2	4
45	The Role of Molecular Imaging in a Muscle-Invasive Bladder Cancer Patient: A Narrative Review in the Era of Multimodality Treatment. Diagnostics, 2021, 11, 863.	2.6	4
46	Our experience in thymic hyperplasia using 67Ga-citrate, 111In-pentetreotide and 201Tl-chloride. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1616-1616.	6.4	3
47	AutoSPET: An SPM plugin to automatize neuroimages PET analysis. Interdisciplinary Sciences, Computational Life Sciences, 2013, 5, 225-232.	3.6	3
48	An Innovative Framework for Bioimage Annotation and Studies. Interdisciplinary Sciences, Computational Life Sciences, 2018, 10, 544-557.	3.6	3
49	FDG-CT/PET false positive case in hip prosthesis: a clue to avoid error. Radiology Case Reports, 2021, 16, 2601-2604.	0.6	2
50	64Cu-Radiopharmaceuticals. , 2020, , 115-130.		1
51	Annotations for clinical data enrichment. , 2021, , .		1